| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1042439117 |
| P356 | DOI | 10.1038/SJ.BJC.6601168 |
| P932 | PMC publication ID | 2376928 |
| P698 | PubMed publication ID | 12915869 |
| P5875 | ResearchGate publication ID | 10615620 |
| P2093 | author name string | M Hennig | |
| C Peschel | |||
| H Bernhard | |||
| C von Schilling | |||
| F Lordick | |||
| R Bredenkamp | |||
| P2860 | cites work | Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer | Q33502768 |
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group | Q42557591 | ||
| Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus | Q43988072 | ||
| Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus | Q68122887 | ||
| Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors | Q73080403 | ||
| Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity | Q73492635 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus | Q74545971 | ||
| The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent | Q78846264 | ||
| Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule | Q95720952 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irinotecan | Q412197 |
| docetaxel | Q420436 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 630-633 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer | |
| P478 | volume | 89 |
| Q33591847 | A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer |
| Q46896374 | A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma |
| Q39252283 | Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane |
| Q33367321 | Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients |
| Q94950682 | Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study |
| Q36616002 | Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial |
| Q44159329 | Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study |
| Q37359769 | Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group |
| Q38542060 | Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma |
| Q79443185 | Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation |
| Q92713111 | Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma |
| Q43194164 | Esophageal cancer chemotherapy: recent advances. |
| Q33433032 | Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy |
| Q38704834 | Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma |
| Q36341551 | Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation |
| Q36996728 | New and emerging combination therapies for esophageal cancer |
| Q46647131 | Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer |
| Q34348291 | Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancer |
| Q34543795 | Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer |
| Q37235047 | Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer |
| Q34056960 | Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. |
| Q36376439 | Recent developments in the systemic therapy of advanced gastroesophageal malignancies |
| Q46681066 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma |
| Q33377084 | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience |
| Q34388021 | Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma |
| Q36842786 | Second-line therapy for esophageal cancer |
| Q53259440 | Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy. |
| Q42769520 | Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine? |
| Q44887891 | The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. |
| Q37321790 | Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer |
| Q81891664 | [Palliative treatment of esophageal carcinoma: chemotherapy and palliative care] |
Search more.